Literature DB >> 2436843

Translation products of pre-S(1), pre-S(2) regions and the S gene of hepatitis B virus: susceptibility of their antigenic activities to treatment with heat, urea, formalin or pepsin.

H Ohnuma, A Machida, E Takai, F Tsuda, H Miyamoto, T Tanaka, K Oda, S Usuda, T Nakamura, Y Miyakawa.   

Abstract

Hepatitis B subviral particles, purified from plasma of asymptomatic carriers seropositive for hepatitis B e antigen, were treated with various conditions reported for the processing of vaccines. Thereafter, antigenic activities displayed by the translation products of pre-S(1), pre-(2) regions and the S gene were determined with monoclonal antibodies, and the reactivity for polyalbumin receptor was tested. Heating at 100 degrees C for 1.5 min and then at 65 degrees C for 10 h preserved more than 1/2 of antigenic activities representing products of pre-S(1), pre-S(2) regions and the S gene. After incubation in the presence of 8 M urea at 37 degrees C for 4 h, more than 2/3 of antigenic activities still remained. The antigenic activity of the S gene product was decreased to 2/3 and that of pre-S(2) region product to 1/3, after treatment with formalin at the final concentration of 1:4000 at 37 degrees C for 72 h, whereas the activity of pre-S(1) region product was affected drastically. Although 1/5 of the antigenic activity of the S gene product survived the digestion with pepsin for 18 h, antigenic activities of pre-S(1) and pre-S(2) region products were destroyed almost completely. Polyalbumin receptor, borne by the pre-S(2) region product, was lost by pepsin digestion also. Based on the results obtained, heating may be most appropriate for sterilizing plasma-derived hepatitis B particles for use as a vaccine, because it is reliably virucidal and would not affect the protective efficacy to an extent as the other virucidal methods would.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2436843      PMCID: PMC1542458     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Antibody to the receptor for polymerized human serum albumin in acute and persistent infection with hepatitis B virus.

Authors:  H Okamoto; S Usuda; M Imai; K Tachibana; E Tanaka; T Kumakura; M Itabashi; E Takai; F Tsuda; T Nakamura
Journal:  Hepatology       Date:  1986 May-Jun       Impact factor: 17.425

2.  Partial amino acid sequence of two major component polypeptides of hepatitis B surface antigen.

Authors:  D L Peterson; I M Roberts; G N Vyas
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

3.  Hepatitis virus: effect of heat on the infectivity and antigenicity of the MS-1 and MS-2 strains.

Authors:  S Krugman; J P Giles; J Hammond
Journal:  J Infect Dis       Date:  1970-11       Impact factor: 5.226

4.  Biology of hepatitis B virus.

Authors:  P Tiollais; P Charnay; G N Vyas
Journal:  Science       Date:  1981-07-24       Impact factor: 47.728

5.  Demonstration of albumin receptors on isolated human hepatocytes by light and scanning electron microscopy.

Authors:  A Trevisan; F Gudat; R Guggenheim; G Krey; U Dürmüller; G Lüond; M Düggelin; J Landmann; P Tondelli; L Bianchi
Journal:  Hepatology       Date:  1982 Nov-Dec       Impact factor: 17.425

6.  Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen.

Authors:  P Valenzuela; P Gray; M Quiroga; J Zaldivar; H M Goodman; W J Rutter
Journal:  Nature       Date:  1979-08-30       Impact factor: 49.962

7.  A receptor for polymerized human and chimpanzee albumins on hepatitis B virus particles co-occurring with HBeAg.

Authors:  M Imai; Y Yanase; T Nojiri; Y Miyakawa; M Mayumi
Journal:  Gastroenterology       Date:  1979-02       Impact factor: 22.682

8.  Synthesis and assembly of hepatitis B virus surface antigen particles in yeast.

Authors:  P Valenzuela; A Medina; W J Rutter; G Ammerer; B D Hall
Journal:  Nature       Date:  1982-07-22       Impact factor: 49.962

9.  A 49,000-dalton polypeptide bearing all antigenic determinants and full immunogenicity of 22-nm hepatitis B surface antigen particles.

Authors:  S Mishiro; M Imai; K Takahashi; A Machida; T Gotanda; Y Miyakawa; M Mayumi
Journal:  J Immunol       Date:  1980-04       Impact factor: 5.422

10.  Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; W R Oleszko; D C William; R Sadovsky; J M Morrison; A Kellner
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

View more
  2 in total

1.  HBsAg-induced antigen-specific T and B lymphocyte responses in chronic hepatitis B virus carriers and immune individuals.

Authors:  A Fernan; C J Cayzer; W G Cooksley
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

2.  Igh allotype-linked control of immune complex-type hypersensitivity induced by hepatitis B surface antigen.

Authors:  H Y Lei; S C Lee
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.